Skip Navigation


Carcinogenesis Advance Access originally published online on August 27, 2008
Carcinogenesis 2008 29(11):2236-2242; doi:10.1093/carcin/bgn204
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/11/2236    most recent
bgn204v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Maillard, C.M.
Right arrow Articles by Noël, A.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maillard, C.M.
Right arrow Articles by Noël, A.C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors

C.M. Maillard1,*, C. Bouquet2, M.M. Petitjean1, M. Mestdagt1, E. Frau2, M. Jost1, A.M. Masset1, P.H. Opolon2, F. Beermann4, M.M. Abitbol3, J.M. Foidart1,5, M.J. Perricaudet2 and A.C. Noël1

1 Laboratory of Tumor and Development Biology, GIGA-Cancer, Tour de Pathologie (B23), University of Liège, Sart-Tilman, B-4000 Liège, Belgium
2 CNRS UMR 8121 Univ Paris Sud, Vectorologie et Transfert de Gènes, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
3 Centre d'études et de Recherches Thérapeutiques en Ophtalmologie, Faculté de Médecine Necker, 156 rue de Vaugirard, 75015 Paris, France
4 Swiss Institute for Experimental Cancer Research (ISREC), Faculty of life Sciences, Ecole Polytechnique Fédérable de Lausanne (EPFL), Chemin de Boveresses 155, CH-1066 Epalinges, Switzerland
5 Department of Gynecology and Obstetrics, CHU, B-4000 Liège, Belgium

* To whom correspondence should be addressed. Laboratory of Tumor Biology and Development, Institute of Pathology CHU-B23, University of Liège, Sart-Tilman, B-4000 Liège, Belgium. Tel: +32 4 366 25 69; Fax: +32 4 366 29 36; Email: cmaillard{at}ulg.ac.be

Correspondence may also be addressed to A.C.Nöel. Email: agnes.noel{at}ulg.ac.be

Plasminogen activator inhibitor-1 is known to play a paradoxical positive role in tumor angiogenesis, but its contribution to metastatic spread remains unclear. We studied the impact of plasminogen activator inhibitor (PAI)-1 deficiency in a transgenic mouse model of ocular tumors originating from retinal epithelial cells and leading to brain metastasis (TRP-1/SV40 Tag mice). PAI-1 deficiency did not affect primary tumor growth or vascularization, but was associated with a smaller number of brain metastases. Brain metastases were found to be differentially distributed between the two genotypes. PAI-1-deficient mice displayed mostly secondary foci expanding from local optic nerve infiltration, whereas wild-type animals displayed more disseminated nodules in the scissura and meningeal spaces. SuperArray GEarray analyses aimed at detecting molecules potentially compensating for PAI-1 deficiency demonstrated an increase in fibroblast growth factor-1 (FGF-1) gene expression in primary tumors, which was confirmed by reverse transcription–polymerase chain reaction and western blotting. Our data provide the first evidence of a key role for PAI-1 in a spontaneous model of metastasis and suggest that angiogenic factors, such as FGF-1, may be important for primary tumor growth and may compensate for the absence of PAI-1. They identify PAI-1 and FGF-1 as important targets for combined antitumor strategies.

Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; FGF-1, fibroblast growth factor-1; KO, knockout; Maspin, mammary serine protease inhibitor; MMP, matrix metalloproteinase; mRNA, messenger RNA; PA, plasminogen activator; PAI, plasminogen activator inhibitor; RPE, retinal pigmented epithelium; RT–PCR, reverse transcription–polymerase chain reaction; Serpin, serine protease inhibitors; TIMP, tissue inhibitor of metalloprotease; tPA, tissue-type plasminogen activator; TRP-1, tyrosine-related protein 1; uPA, urokinase-type plasminogen activator; VEGF, vascular endothelial growth factor; WT, wild-type

Received April 28, 2008; revised August 21, 2008; accepted August 22, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.